Recently, he has done cross-border deals for Medigene, a publicly traded biotech company based in Munich, with Bluebird Bio, a high-profile Boston-based gene therapy company that offers unique therapies in sickle cell disease. This is Medigene's first foray into T-cell receptors. The deal is worth more than $1 billion. He also was involved in a deal for KaloBios, working with the company's new management team in the wake of CEO Martin Shkreli's indictment. Hogan Lovells renegotiated the letter of intent, obtained debtor-in-possession financing, and acquired a drug from Savant HWP, saving 6-10 months of the review window. Most notably, he was involved in advising Verily in a joint venture with GlaxoSmithKline to form Galvani Bioelectronics Limited, which has plans to develop implantable devices for chronic diseases.